Amgen And Biovitrum Sign License Agreement For Innovative Treatment Of Type 2 Diabetes
08 sept. 2003 09h13 HE
|
Biovitrum AB
STOCKHOLM, Sweden, Sept. 8, 2003 (PRIMEZONE) -- Amgen Inc. (Nasdaq:AMGN) and Biovitrum AB today announced that they have signed a multifaceted agreement under which Amgen receives exclusive rights to...
Biovitrum and GlaxoSmithKline to Focus Efforts on Developing Highly Selective 5-HT2c Receptor Agonists
22 mai 2003 05h38 HE
|
Biovitrum AB
STOCKHOLM, Sweden, May 22, 2003 (PRIMEZONE) -- Biovitrum AB today announced that Biovitrum and GlaxoSmithKline (Other OTC:GLAXF) have jointly decided to focus their efforts on the development of...
Biovitrum Initiates Clinical Phase IIb Study of Anti-Obesity Treatment
07 avr. 2003 04h09 HE
|
Biovitrum AB
STOCKHOLM, Sweden, April 7, 2003 (PRIMEZONE) -- Biovitrum today announced the start of a clinical Phase IIb study of the anti-obesity compound BVT.933 (GW876167), a 5-HT2C receptor agonist for the...
Biovitrum initiates Phase II Study with its Diabetes Candidate Drug BVT.3498; Primary End-point is Improved Glycaemia Control
25 mars 2003 04h47 HE
|
Biovitrum AB
STOCKHOLM, Sweden, March 25, 2003 (PRIMEZONE) -- Biovitrum today announced the initiation of a Phase II clinical trial of BVT.3498, its lead compound for type 2 diabetes. Safety, tolerability and...
Biovitrum initiates Phase II Study with its Diabetes Candidate Drug BVT.3498; Primary End-point is Improved Glycaemia Control
25 mars 2003 04h12 HE
|
Biovitrum AB
STOCKHOLM, Sweden, March 25, 2003 (PRIMEZONE) -- Biovitrum today announced the initiation of a Phase II clinical trial of BVT.3498, its lead compound for type 2 diabetes. Safety, tolerability and...
Biovitrum AB Signs an Agreement with Lundbeck to Produce Protein Therapeutics
14 janv. 2003 04h13 HE
|
Biovitrum AB
STOCKHOLM, Sweden, Jan. 14, 2003 (PRIMEZONE) -- Biovitrum AB today announced a commission agreement with the Danish pharmaceutical company Lundbeck A/S for the production of a protein...
GlaxoSmithKline and Biovitrum Enter Collaboration on Therapies for Obesity and Other Disorders
23 oct. 2002 08h05 HE
|
Biovitrum AB
LONDON and STOCKHOLM, Sweden, Oct. 23, 2002 (PRIMEZONE) -- GlaxoSmithKline plc (NYSE:GSK) ("GSK") and Biovitrum AB, today announced that they have signed a worldwide agreement to develop and...
Biovitrum Announces Collaboration with Biofocus for GPCR Drug Discovery
12 sept. 2002 02h47 HE
|
Biovitrum AB
STOCKHOLM, Sweden, and SITTINGBOURNE, U.K., Sept. 12, 2002 (PRIMEZONE) -- Biovitrum, one of Europe's leading biotech companies, and BioFocus plc, the pioneering collaborative drug discovery company,...
Biovitrum: Swedish Biotech Companies Form New Industry Organization -- 'SwedenBIO'
04 sept. 2002 04h48 HE
|
Biovitrum AB
STOCKHOLM, Sweden, Sept. 4, 2002 (PRIMEZONE) -- SwedenBIO is a new industry association that will work actively to promote the successful establishment of internationally competitive biotechnology...
Biovitrum Announces the Formation of its Scientific Advisory Board
30 juil. 2002 03h49 HE
|
Biovitrum AB
STOCKHOLM, Sweden, July 30, 2002 (PRIMEZONE) -- Biovitrum today announced the formation of its Scientific Advisory Board. The Board will assist Biovitrum's management in the development of the...